EAMA
BMRN icon

EFG Asset Management (Americas)’s BioMarin Pharmaceuticals BMRN Stock Holding History

EFG Asset Management (Americas)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,807
Closed -$2.54M – 124
2024
Q2 		$2.54M Buy
30,807
+10,991
+55% +$915K 0.5% 60
2024
Q1 		$1.73M Sell
19,816
-7,412
-27% -$664K 0.53% 52
2023
Q4 		$2.63M Buy
27,228
+432
+2% +$38.2K 0.57% 61
2023
Q3 		$2.37M Buy
26,796
+10,194
+61% +$907K 0.57% 54
2023
Q2 		$1.44M Buy
+16,602
New +$1.56M 0.33% 82
2021
Q1 		– Sell
-2,976
Closed -$261K – 139
2020
Q4 		$261K Sell
2,976
-60
-2% -$4.76K 0.05% 127
2020
Q3 		$231K Sell
3,036
-35,567
-92% -$3.6M 0.05% 128
2020
Q2 		$4.76M Sell
38,603
-10,367
-21% -$1.03M 1.24% 30
2020
Q1 		$4.14M Sell
48,970
-6,416
-12% -$553K 1.33% 24
2019
Q4 		$4.68M Buy
55,386
+21,222
+62% +$1.6M 1.24% 26
2019
Q3 		$2.3M Sell
34,164
-492
-1% -$37.9K 0.69% 60
2019
Q2 		$2.97M Buy
34,656
+535
+2% +$45.8K 0.84% 52
2019
Q1 		$3.03M Sell
34,121
-5,377
-14% -$498K 0.92% 49
2018
Q4 		$3.36M Buy
39,498
+4,019
+11% +$382K 1.21% 28
2018
Q3 		$3.44M Buy
35,479
+6,467
+22% +$646K 0.99% 37
2018
Q2 		$2.73M Buy
29,012
+17,340
+149% +$1.52M 0.83% 38
2018
Q1 		$946K Buy
11,672
+1,250
+12% +$107K 0.39% 59
2017
Q4 		$929K Buy
10,422
+3,069
+42% +$267K 0.34% 64
2017
Q3 		$684K Buy
7,353
+1,788
+32% +$158K 0.26% 71
2017
Q2 		$505K Buy
5,565
+1,976
+55% +$180K 0.19% 89
2017
Q1 		$315K Buy
+3,589
New +$319K 0.12% 99

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

EFG Asset Management (Americas)'s BMRN Position: Q3 2024 in Review

EFG Asset Management (Americas) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 30,807 shares — an estimated $2.54M sold.

EFG Asset Management (Americas) first reported a position in BMRN in Q1 2017 and held it in 21 quarters. The position peaked at $4.76M in Q2 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • EFG Asset Management (Americas) reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EFG Asset Management (Americas) sold 30,807 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.54M.
  • EFG Asset Management (Americas) first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 21 quarters.
  • EFG Asset Management (Americas)'s BioMarin Pharmaceuticals position peaked at $4.76M in Q2 2020.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on EFG Asset Management (Americas)'s 13F filing for Q3 2024, filed 12 Nov 2024.